Login to Your Account



AASLD 2015

Gilead, BMS push ahead with HCV combos, give new hope to GT3 patients

By Michael Fitzhugh
Staff Writer

Monday, November 16, 2015

SAN FRANCISCO – New clinical data from Gilead Sciences Inc. and Bristol-Myers Squibb Co, presented at the AASLD Annual Meeting added support to the drugmakers' cases for the efficacy of therapeutic combinations capable of battling HCV.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription